Interpol is on the hunt for fugitives accused of such crimes as ivory smuggling. illegal logging, and trafficking live animals
The cosmetics retailer is facing a lawsuit
The oil market has moved beyond the Keystone XL pipeline
A new tool detects computer malware that’s watching your every move
The provider of high-interest business loans nears an IPO, on the strength of its data-powered credit analysis—and a network of shady brokers
Nike expects revenue from women to outpace its men's business.
Twist, stretch, twirl: a day in the life of a candy cane
Educational Credit Management, a guarantor and collector of student loans, wants to buy 56 campuses from Corinthian Colleges
The novelty items are hot for retailers large and small
Santa Clara, Calif.
Founders: Dr. Gerrit Klaerner, Dr. Scott Rocklage, Dr. Detlef Albrecht, and Dr. Jerry Buysse
VC Investment over the last four quarters: $33 million
In October 2007, Relypsa was spun out of Amgen (AMGN) by the founders of a previous biotech startup, Ilypsa, which the biotech company had acquired for $420 million earlier that year. The 47-employee company is developing treatments for hyperkalemia, a potentially deadly condition in patients with heart and kidney disease. By acting in the gastrointestinal tract only, Relypsa's drugs would reduce the risk of side effects that can occur with treatments that are absorbed into the bloodstream.
Key to startup success: "... Intense focus, speed, and efficient use of capital. We have been able to take our lead product program from the initial clinical testing stage in a Phase 1 trial [investigational new drug] to Phase 2 clinical development in nine months, something that most drug discovery and development startups typically achieve ... in three to four years."